IDEXX Laboratories, Inc. $IDXX Shares Purchased by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 19,642 shares of the company’s stock after acquiring an additional 212 shares during the quarter. Mutual of America Capital Management LLC’s holdings in IDEXX Laboratories were worth $10,535,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. MorganRosel Wealth Management LLC acquired a new stake in IDEXX Laboratories in the 1st quarter valued at $26,000. Opal Wealth Advisors LLC purchased a new position in IDEXX Laboratories in the 2nd quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after purchasing an additional 30 shares in the last quarter. Ameritas Advisory Services LLC purchased a new position in IDEXX Laboratories in the 2nd quarter valued at $36,000. Finally, WPG Advisers LLC purchased a new position in IDEXX Laboratories in the 1st quarter valued at $37,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on IDXX. Leerink Partners raised their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. JPMorgan Chase & Co. raised their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a report on Monday, August 4th. BTIG Research raised their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Jefferies Financial Group began coverage on IDEXX Laboratories in a report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price objective on the stock. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $656.50.

Insider Transactions at IDEXX Laboratories

In related news, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the sale, the director directly owned 262 shares in the company, valued at approximately $169,600.46. The trade was a 89.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Nimrata Hunt sold 1,200 shares of the business’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $656.53, for a total transaction of $787,836.00. Following the completion of the sale, the executive vice president owned 16,807 shares in the company, valued at approximately $11,034,299.71. This trade represents a 6.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock worth $34,293,468 in the last 90 days. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Down 0.3%

NASDAQ IDXX opened at $635.40 on Monday. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The business’s fifty day simple moving average is $639.99 and its 200-day simple moving average is $551.18. The firm has a market cap of $50.83 billion, a PE ratio of 52.91, a P/E/G ratio of 4.11 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the previous year, the firm earned $2.44 EPS. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.